Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the Q3 2025 Tether Pharmaceutical Industries Limited Earnings Conference Call. My name is Alex and I'll be coordinating today's call. If you'd like to ask a question at the end of the presentation, please press star followed by one on your telephone keypad. I'll now hand it over to Chris Stevo, SVP, Investor Relations. Please go ahead. Thank you, Alex. Good morning and good afternoon, everyone. In a moment, I'll hand the call over to my CEO, Richard Francis, But before I do that, it is my duty and my honor to remind you of our forward-looking statements. Today on this call, we'll be making forward-looking statements, and we undertake no obligation to update those statements after today's call. If you have any questions regarding forward-looking statements, please feel free to see our SEC filings under Forms 10-Q and 10-K in the relevant sections. And with that, Richard Francis. Thanks, Chris, and good morning, good afternoon, everybody. Thank you for joining the call today. On the call today, I'll be joined by Dr. Eric Hughes, head of R&D and chief medical officer, and Eli Khalif, the CEO of Teva Pharmaceuticals. So starting with, as I always do, the Pivot to Growth strategy. This is a strategy that have guided Teva for the last three years. A strategy based on the four pillars, deliver on our growth engines, which is all about driving Esteto, Uceti, and Ejovi, our innovative portfolio, stepping up innovation, which Eric will talk to you about, but the great progress we're making across our innovative pipeline, sustained generics powerhouse, and the work we've done to stabilize our generics business, and then focus the business. And we'll give you an update on where we are with our transformation of Teva, our $700 million cost-saving programs, as...